XBiome Launches First Beauty-focused Microbiome Subsidiary, Unknown Beauty, with Filing of IPO Prospectus

April 26,The unveiling and launch ceremony of Shenzhen Xbiome Medical Technology Co., Ltd. (hereinafter referred to as "Xbiome") was successfully held.Unknown Beauty, a subsidiary of Xbiome Holdings focusing on the beauty and health industry, is committed to building an exclusive microbiome brand for the beauty industry, Unknown Zhi Mei, based on Xbiome's leading microbiome technology platform and product platform, opening a new chapter in the deep integration of serious medical technology and high-end beauty.

The ceremony, themed "Gut Renewal · Xbiome Beauty," was attended by Sun Jingyuan, General Manager of Glee Medical Device Co., Ltd., Zhao Guangquan, Chairman of Jumei Group, Dr. Tan Yan, Co-founder and CEO of Xbiome, Hao Yi, Co-founder, COO, and General Manager of Xbiome Beauty, and other distinguished guests who jointly witnessed the milestone moment of Xbiome Beauty entering the large health industry in beauty. During the ceremony, Xbiome Beauty and Jumei Group officially signed a strategic cooperation agreement.Jumei Group will promote the Xbiome FMT product series across China and officially become the first client enterprise of Xbiome.

Hao Yi, Co-founder and COO of Xbiome, General Manager of Xbiome Me, stated in his speech,Unknown Beauty is the first subsidiary established by Xbiome in the professional marketing field of the beauty industry.Marks a key step in Xbiome's "serious medical care + big health" dual-driven strategy. Xbiome will integrate its industry-leading "AI + BT" technology platform, as well as its cGMP-compliant product manufacturing and quality control system.Building a Microecological Science Brand in the Beauty Industry Track – Xbiome,Provide users with safe, effective, and traceable gut microbiota health solutions.

Hao Yi emphasized that Xbiome will persist.Rooted in scientific research, centered on users, and focused on channels,Fully Empower Partners to Build a New Ecosystem for Beauty and Health, and Jointly Explore the Billion-Dollar Endogenous Anti-Aging Blue Ocean.

Sun Jingyuan, General Manager of Gree Medical Device Co., Ltd., attended the ceremony and delivered a speech. Sun Jingyuan stated that Gree Medical will deeply collaborate with Xbiome to provide full support for Xbiome's "Beauty Industry + Microecology," approaching the beauty industry with medical precision and creating beauty through the power of technology. Sun Jingyuan noted that the integration and support of various resources have enabled Xbiome to possessMedical-grade Precision, Research-level Strength, Beauty-industry ExperienceThe three core advantages form a significant distinction compared to ordinary medical aesthetics and light medical aesthetic projects, possessing tremendous innate superiority.

Guangquan Zhao, Vice President of Jumei Group, stated in his speech,The beauty industry is upgrading from "superficial modifications" to root anti-aging and internal health.Unknown Beauty, backed by Xbiome's solid research data, rigorous medical attitude, and leading FMT technology barriers, is Jumei Group's preferred partner in laying out the technology-based anti-aging track. This signing represents Jumei's high recognition of Unknown Beauty's technology and products, and it is expected that the cooperation between the two parties will make the microbiome the next core growth engine of the beauty industry.

Xbiome Co. Ltd.'s co-founder and CEO, Dr. Tan Yan, pointed out in his concluding remarks that Xbiome has深耕the field of gut microbiota for many years, possessing leading research capabilities and an industrialization foundation. FMT technology not only demonstrates significant value in serious medical fields but also...EntericAnti-aging, Metabolism Management, Endogenous Youth StateMedical aesthetics scenarios also have broad application prospects. In the future, Xbiome will continue to increase R&D investment to provide technical support and product iteration for Xbiome’s aesthetics solutions, using science to redefine beauty and enhance the health experience of users in the beauty industry.

This ceremony marks a new starting point for Xbiome Aesthetics and serves as an industry milestone for the systematic implementation of intestinal microbiome technology in the broader health and beauty sector. Xbiome will leverage its cutting-edge "AI + BT"-driven scientific technology to empower its core aesthetic brand, Xbiome ZhiMei, and further expand its presence in the health and wellness market. In 2021, Xbiome became the first Asian pharmaceutical company* to receive FDA approval for FMT drug clinical trials in the United States, establishing a production and management system recognized and regulated by the FDA. The establishment of Xbiome Aesthetics signifies that Xbiome will apply its entire drug-grade microbiome technology system to the beauty industry, collaborating with industry partners to build a new ecosystem where health and beauty coexist.* Source: Informa Pharma Intelligence

-End-